Physician profile
Amy E Ramser
NPI 1881057073
$33,804.61
in general payments reported to CMS, 2019-2025
14 companies · $383 in 2025
The $383 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $153 · 2021: $371 · 2022: $566 · 2023: $22.48 · 2024: $100 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $406 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $405.64 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $32,092.32 | 2019-2025 | |
| Abbvie INC. | $340.79 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $275.25 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $252.01 | 2021-2025 | Dupixent |
| Lilly USA, LLC | $148.43 | 2020-2022 | |
| Genentech USA, INC. | $140.37 | 2019 | |
| Galderma Laboratories, L.P. | $130.18 | 2021-2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $116.03 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $86.98 | 2021 | |
| Amgen INC. | $68.85 | 2024-2025 | Otezla, Otezla |
| Ucb, INC. | $62.12 | 2025 | Bimzelx |
| Janssen Biotech, INC. | $54.98 | 2022-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $18.47 | 2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $17.83 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Ramser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.